BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 9579633)

  • 1. Pharmacological actions of sulodexide.
    Ofosu FA
    Semin Thromb Hemost; 1998; 24(2):127-38. PubMed ID: 9579633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithrombotic activity of dermatan sulphates, heparins and their combination in an animal model of arterial thrombosis.
    Iacoviello L; D'Adamo MC; Pawlak K; Polishchuck R; Wollny T; Buczko W; Donati MB
    Thromb Haemost; 1996 Dec; 76(6):1102-7. PubMed ID: 8972038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms for the anticoagulant effect of heparin and related polysaccharides.
    Ofosu FA
    Nouv Rev Fr Hematol (1978); 1988; 30(3):155-60. PubMed ID: 2971155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombotic and anticomplementary properties of a very low molecular mass dermatan sulfate.
    Fabiana Alberto M; Giaquinta Romero D; Lazzari M; Calabrese GC
    Thromb Res; 2008; 122(1):109-16. PubMed ID: 17936880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
    Melo FR; Mourão PA
    Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fucosylated chondroitin sulfate as a new oral antithrombotic agent.
    Fonseca RJ; Mourão PA
    Thromb Haemost; 2006 Dec; 96(6):822-9. PubMed ID: 17139379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unbalanced effects of dermatan sulfates with different sulfation patterns on coagulation, thrombosis and bleeding.
    Vicente CP; Zancan P; Peixoto LL; Alves-Sá R; Araújo FS; Mourão PA; Pavão MS
    Thromb Haemost; 2001 Nov; 86(5):1215-20. PubMed ID: 11816710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic properties of a low molecular weight dermatan sulfate: comparison with unfractionated dermatan sulfate.
    Dol F; Petitou M; Lormeau JC; Choay J; Caranobe C; Sie P; Saivin S; Houin G; Boneu B
    J Lab Clin Med; 1990 Jan; 115(1):43-51. PubMed ID: 2299256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Dermatan sulfate and the prevention of experimental venous thrombosis].
    Desnoyers P; Bara L; Samama M
    Pathol Biol (Paris); 1989 Jun; 37(6):759-67. PubMed ID: 2674877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different antithrombotic mechanisms among glycosaminoglycans revealed with a new fucosylated chondroitin sulfate from an echinoderm.
    Pacheco RG; Vicente CP; Zancan P; Mourão PA
    Blood Coagul Fibrinolysis; 2000 Sep; 11(6):563-73. PubMed ID: 10997797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological profile of sulodexide.
    Hoppensteadt DA; Fareed J
    Int Angiol; 2014 Jun; 33(3):229-35. PubMed ID: 24936531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A survey of the clinical experience with dermatan sulfate.
    Gianese F; Lucchelli PE
    Semin Thromb Hemost; 1991; 17 Suppl 2():199-204. PubMed ID: 1948090
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacological properties of dermatan sulfate, of a low molecular weight dermatan sulfate and of two oversulfated derivatives.
    Dol F; Petitou M; Choay J; Sie P; Houin G; Boneu B
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(6):851-7. PubMed ID: 2483702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of polysaccharides enriched in 2,4-disulfated fucose units on coagulation, thrombosis and bleeding. Practical and conceptual implications.
    Fonseca RJ; Santos GR; Mourão PA
    Thromb Haemost; 2009 Nov; 102(5):829-36. PubMed ID: 19888516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Additive thrombin inhibition by fast moving heparin and dermatan sulfate explains the anticoagulant effect of sulodexide, a natural mixture of glycosaminoglycans.
    Cosmi B; Cini M; Legnani C; Pancani C; Calanni F; Coccheri S
    Thromb Res; 2003 Mar; 109(5-6):333-9. PubMed ID: 12818259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale behind the development of low molecular weight heparin derivatives.
    Hirsh J; Ofosu F; Buchanan M
    Semin Thromb Hemost; 1985 Jan; 11(1):13-6. PubMed ID: 2579436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Slight differences in sulfation of algal galactans account for differences in their anticoagulant and venous antithrombotic activities.
    Fonseca RJ; Oliveira SN; Melo FR; Pereira MG; Benevides NM; Mourão PA
    Thromb Haemost; 2008 Mar; 99(3):539-45. PubMed ID: 18327402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological and clinical studies with Lomoparan, a low molecular weight glycosaminoglycan.
    Nurmohamed MT; Fareed J; Hoppensteadt D; Walenga JM; ten Cate JW
    Semin Thromb Hemost; 1991; 17 Suppl 2():205-13. PubMed ID: 1948091
    [No Abstract]   [Full Text] [Related]  

  • 19. Dual effects of sulfated D-galactans from the red algae Botryocladia occidentalis preventing thrombosis and inducing platelet aggregation.
    Farias WR; Nazareth RA; Mourão PA
    Thromb Haemost; 2001 Dec; 86(6):1540-6. PubMed ID: 11776325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of heparin, dermatan sulfate and of their association on the inhibition of venous thrombosis growth in the rabbit.
    Carrie D; Caranobe C; Gabaig AM; Larroche M; Boneu B
    Thromb Haemost; 1992 Dec; 68(6):637-41. PubMed ID: 1287877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.